Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study

Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections

(2016) A. Russo et al.   CLINICAL MICROBIOLOGY AND INFECTION

How to stratify patients at risk for resistant bugs in skin and soft tissue infections?

(2016) Cristina Vazquez Guillamet et al.   CURRENT OPINION IN INFECTIOUS DISEASES

A Thorough QT Study To Evaluate the Effects of Therapeutic and Supratherapeutic Doses of Delafloxacin on Cardiac Repolarization

(2015) Jeffrey S. Litwin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy

(2015) Françoise Van Bambeke   Future Microbiology

A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections

(2015) William O’Riordan et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin

(2015) Jeff Kingsley et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Impact of Evolving Epidemiology on Treatments for Complicated Skin and Skin Structure Infections: The Surgical Perspective

(2015) Philip S. Barie et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

(2014) Martin E Stryjewski et al.   BMC INFECTIOUS DISEASES

Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America

(2014) Dennis L. Stevens et al.   CLINICAL INFECTIOUS DISEASES

Economic outcomes of inappropriate initial antibiotic treatment for complicated skin and soft tissue infections: a multicenter prospective observational study

(2014) B.A. Lipsky et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future

(2013) K. A. Rodvold et al.   CLINICAL INFECTIOUS DISEASES

Initial Treatment Failure in Patients with Complicated Skin and Skin Structure Infections

(2013) Ariel Berger et al.   Surgical Infections

New antibiotics for bad bugs: where are we?

(2013) Matteo Bassetti et al.   Annals of Clinical Microbiology and Antimicrobials

Introduction: Solving the Clinical Problem of Vancomycin Resistance

(2012) Robert C. Moellering et al.   CLINICAL INFECTIOUS DISEASES

Combination Therapy for Treatment of Infections with Gram-Negative Bacteria

(2012) P. D. Tamma et al.   CLINICAL MICROBIOLOGY REVIEWS

Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess

(2012) Jenana Halilovic et al.   JOURNAL OF INFECTION

Risk Factors for Mixed Complicated Skin and Skin Structure Infections To Help Tailor Appropriate Empiric Therapy

(2012) Marya Zilberberg et al.   Surgical Infections

Outcomes and management costs in patients hospitalized for skin and skin-structure infections

(2010) Kamal M.F. Itani et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin againstStaphylococcus aureus

(2010) Sandrine Lemaire et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Complicated skin and soft tissue infection

(2010) M. S. Dryden   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

(2008) M. Rybak et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY